South Korea Dry Age-Related Macular Degeneration (AMD) Market Research Report By Stage (early age-related macular degeneration, intermediate age-related macular degeneration, late age-related macular degeneration), By Age Group (above 75 years, above 60 years, above 40 years), By Diagnosis and Treatment (treatment, diagnosis), By Route of Administration (oral, injectables) and By End Users (hospitals clinics, diagnostic centers, academic research institutes)-Forecast to 2035

South Korea Dry Age-Related Macular Degeneration (AMD) Market Overview

As per MRFR analysis, the South Korea Dry Age-Related Macular Degeneration (AMD) Market Size was estimated at 110.0 (USD Million) in 2023. The South Korea Dry Age-Related Macular Degeneration (AMD) Market Industry is expected to grow from 120.0(USD Million) in 2024 to 320.0 (USD Million) by 2035. The South Korea Dry Age-Related Macular Degeneration (AMD) Market CAGR (growth rate) is expected to be around 9.326% during the forecast period (2025-2035).

Key South Korea Dry Age-Related Macular Degeneration (AMD) Market Trends Highlighted

The South Korea Dry Age-Related Macular Degeneration (AMD) market is experiencing noteworthy trends driven by the increasing aging population in the country. With a significant portion of its population over the age of 65, there is a growing prevalence of AMD in South Korea, thereby creating a heightened demand for effective treatment options and healthcare solutions. Government initiatives promoting eye health awareness, along with advancements in diagnostic technologies, are also key market drivers contributing to the growth of this sector. This focus on healthcare is visible in various public health campaigns organized by the Ministry of Health and Welfare, which strive to educate the population about the importance of early detection and management of AMD.

Innovative therapy fields like gene therapy and new pharmacological approaches are making South Korea increasingly invest in R&D, which creates business opportunities for foreign markets. Moreover, the strong focus on biotechnological and pharmaceutical innovation presents a window of opportunities for emerging firms to seek alliances with large companies so as to hasten the development and marketing of their products. In addition, there exists an opportunity to improve telemedicine monitoring and management of AMD and enhance patient outcomes as South Korea further invests in healthcare technology. There is also a recent trend of more collaboration between educational institutions and healthcare providers to facilitate research activities directed toward AMD treatment.

Advanced clinical trials are becoming more common, and there is a concerted effort to integrate artificial intelligence into diagnostic processes, streamlining early detection methods. Additionally, a growing awareness among consumers about the significance of nutrition and lifestyle modifications in managing AMD is shaping market dynamics, encouraging thorough discussions on the potential of various health supplements and dietary plans aimed at slowing disease progression. Overall, these combined elements signify a proactive approach to addressing AMD within South Korea's healthcare landscape.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

South Korea Dry Age-Related Macular Degeneration (AMD) Market Drivers

Increasing Aging Population

The South Korea Dry Age-Related Macular Degeneration (AMD) Market Industry is witnessing significant growth due to the increasing aging population in the region. According to the Korean Statistics Authority, the proportion of citizens aged 65 and older is projected to rise from 16.5% in 2020 to approximately 24.1% by 2030. This demographic trend results in a higher prevalence of age-related diseases, notably AMD, which is one of the leading causes of blindness among the elderly.With a growing elderly population, there is an increased demand for AMD screening, diagnosis, and effective treatment options. Health organizations such as the Korea National Institute of Health are actively promoting awareness and education about AMD, further driving the market's growth. The government’s initiatives to enhance healthcare services specifically designed for older adults will significantly contribute to the growth of the South Korea Dry Age-Related Macular Degeneration (AMD) Market.

Advancements in Treatment Options

Technological advancements in medical science have propelled the South Korea Dry Age-Related Macular Degeneration (AMD) Market Industry. The development of innovative therapies and pharmacological interventions has expanded the treatment options available to patients. Reports from the Ministry of Food and Drug Safety show that new drugs targeting AMD have been registered and are undergoing clinical trials, enhancing treatment efficacy. Moreover, the South Korean government has been supportive of biotechnology firms working on AMD therapeutics, which enhances research investments in the sector.This surge in innovation not only supports market growth but also provides a better quality of life for patients suffering from AMD.

Increased Awareness and Screening Programs

The rising awareness of AMD symptoms and the importance of early detection is propelling the South Korea Dry Age-Related Macular Degeneration (AMD) Market Industry. Various health campaigns organized by the Korea Retina Society emphasize the need for regular eye examinations for early detection. The increase in routine eye screenings is evident, with the South Korean government announcing initiatives to subsidize eye examinations for senior citizens, leading to a noticeable increase in screening rates by over 30% in the past four years.By promoting awareness, these programs are expected to lead to an entire increase in AMD diagnoses, ultimately fueling the market's growth.

South Korea Dry Age-Related Macular Degeneration (AMD) Market Segment Insights

Dry Age-Related Macular Degeneration (AMD) Market Stage Insights

The South Korea Dry Age-Related Macular Degeneration (AMD) Market shows a structured segmentation based on the stage of the disease, which includes early, intermediate, and late age-related macular degeneration. Each of these stages presents distinct clinical features and treatment strategies, making them critical in understanding the overall landscape of the market. The early stage often comes with mild symptoms, and while it may go unnoticed, it serves a pivotal role in informing healthcare strategies aimed at early intervention. Intermediate age-related macular degeneration is characterized by more pronounced symptoms and visual disturbances, necessitating a greater focus on patient management to prevent progression to late-stage disease.

This stage is significant in terms of patient care as it often represents a transitional phase where intervention can be most effective, thus helping to maintain the quality of life for patients. Late age-related macular degeneration is the most severe form, leading to substantial vision loss and presenting considerable challenges in terms of treatment and rehabilitation. As the population ages, the incidence of late AMD is expected to rise, making it increasingly relevant for healthcare policies and resource allocation in South Korea, where the elderly population is rapidly growing. The market segmentation reflects these realities, responding to the need for specialized care and treatment options across all stages of AMD. This nuanced understanding of disease progression aids in the formulation of effective healthcare strategies and market demands, directing resources where they are most needed and enhancing patient outcomes.With evolving demographics and increased awareness surrounding eye health, there are ample opportunities within each stage of the disease for innovative treatments and care solutions.

The South Korea Dry Age-Related Macular Degeneration (AMD) Market is not only driven by clinical needs but also influenced by technological advancements and patient education initiatives. Given the significant public health implications, stakeholders in the healthcare industry are focusing on tailored approaches for each stage to optimize treatment efficacy. As a result, the market segmentation around stages of AMD not only informs product development but is also crucial for data-driven strategies that enhance long-term patient outcomes while navigating the complex landscape of aging eye health. As healthcare providers in South Korea adapt to these dynamics, the segmentation of age-related macular degeneration remains an integral aspect of both patient-centered care and industry growth.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Dry Age-Related Macular Degeneration (AMD) Market Age Group Insights

The Age Group segmentation of the South Korea Dry Age-Related Macular Degeneration (AMD) Market highlights the increasing prevalence of AMD among the older population, particularly those above 60 years. This age group acts as a significant driver for the market due to the higher risks associated with aging and vision impairment. The population aged above 75 years often represents a substantial portion of AMD cases, experiencing a greater burden of vision-related issues that necessitate advanced care and treatments. Additionally, individuals aged above 40 years are becoming increasingly aware of AMD, leading to earlier screenings and interventions, which are pivotal in managing the condition effectively.

With South Korea's aging demographic, the demand for tailored healthcare solutions is growing, positioning this market segment for considerable development. The government’s initiatives focusing on elderly health are further driving awareness and encouraging better management practices. The interplay between the rising elderly population and heightened awareness around eye health creates both challenges and opportunities within the South Korea Dry Age-Related Macular Degeneration (AMD) Market, fundamentally influencing trends, healthcare policies, and market dynamics in the region.

Dry Age-Related Macular Degeneration (AMD) Market Diagnosis and Treatment Insights

The South Korea Dry Age-Related Macular Degeneration (AMD) Market is characterized by extensive developments in the Diagnosis and Treatment segment, which together are essential in improving patient outcomes. The treatment part is crucial as it typically involves therapies that slow disease progression and manage symptoms, helping to preserve vision for a growing elderly population that is particularly susceptible to AMD. Meanwhile, advancements in diagnostic techniques enhance early detection, thereby enabling timely intervention.

As the prevalence of dry AMD rises in South Korea, driven by an aging demographic, these segments are becoming increasingly significant within the overall market.Notably, technological innovations such as advanced imaging techniques are transforming the diagnostic landscape, facilitating quicker and more accurate diagnoses. Government initiatives aimed at increasing awareness and providing healthcare access further bolster the market, creating substantial opportunities for growth. Moreover, the growing focus on personalized medicine in the treatment segment signals a shift toward more effective and tailored therapies for patients, shaping the future landscape of the South Korea Dry Age-Related Macular Degeneration (AMD) Market.

Dry Age-Related Macular Degeneration (AMD) Market Route of Administration Insights

The South Korea Dry Age-Related Macular Degeneration (AMD) Market is experiencing notable growth, particularly in the Route of Administration segment, which plays a crucial role in treatment efficacy. Within this segment, oral formulations and injectables are key methods for delivering therapeutic agents. Oral administration often offers patient convenience and adherence, making it an attractive option for many patients dealing with chronic conditions like AMD. In contrast, injectables can provide faster therapeutic effects and are essential for delivering specific treatments that require direct action within the eye, highlighting their significance in managing advanced disease stages.As the South Korean population ages and the prevalence of AMD increases, the demand for effective treatment delivery continues to rise.

The government's focus on healthcare improvements and advancements in drug formulations are likely to drive the market, ensuring that both methods capture significant shares of the South Korea Dry Age-Related Macular Degeneration (AMD) Market revenue. Challenges such as the need for patient education and the management of injection procedures persist, but they also present opportunities for further innovation and improvement in treatment approaches.Understanding the South Korea Dry Age-Related Macular Degeneration (AMD) Market dynamics is essential for stakeholders to navigate the growing landscape effectively.

Dry Age-Related Macular Degeneration (AMD) Market End Users Insights

The South Korea Dry Age-Related Macular Degeneration (AMD) Market is significantly influenced by its End Users, which comprise hospitals clinics, diagnostic centers, and academic research institutes. Hospitals clinics lead this sector as they play a crucial role in diagnosing and treating AMD, ensuring patients receive timely interventions. Diagnostic centers contribute significantly by providing essential testing services, which are required for accurate diagnosis and management of the condition. The growing significance of these centers is underscored by advancements in diagnostic technologies that enhance the detection rates of AMD.Academic research institutes are pivotal as they drive innovation through research and development efforts, leading to new treatment modalities and therapeutic approaches, thereby improving patient outcomes.

The combined efforts of these End Users are essential in addressing AMD in South Korea, especially considering the demographic shift towards an aging population and the increasing prevalence of eye-related disorders. As a result, a robust infrastructure centered on these segments supports market growth while enhancing patient care through continuous improvement in treatment methodologies.

South Korea Dry Age-Related Macular Degeneration (AMD) Market Key Players and Competitive Insights

The South Korea Dry Age-Related Macular Degeneration (AMD) Market is a dynamic and rapidly evolving space characterized by a growing emphasis on advanced therapeutic solutions and innovative technologies aimed at addressing the needs of patients affected by AMD. This segment faces varied competition from pharmaceutical firms, medical device manufacturers, and biotechnology companies, each vying for a larger share of the market. The increasing prevalence of AMD due to the aging population combined with rising awareness and screening initiatives create a fertile ground for both established and emerging players. Competitive insights reveal that firms are leveraging strategic alliances, mergers, and product innovations to enhance their market positions.

Key indicators of competitiveness in this market include technological advancements, product pipeline progress, regulatory compliance, and overall patient satisfaction.Bayer has established a significant presence in the South Korea Dry Age-Related Macular Degeneration (AMD) Market, driven by its robust portfolio and strong reputation for innovation. The company's strengths lie in its comprehensive approach to AMD, which includes not only pharmaceutical treatments but also extensive research and development efforts aimed at discovering new solutions. Bayer's marketing and distribution strategies are well-tailored for the South Korean healthcare landscape, where they effectively communicate the advantages of their AMD therapies to both healthcare providers and patients. Their ability to engage in partnerships with local healthcare entities further enhances their market presence, solidifying Bayer's position as a trusted player in providing medications that cater to the specific needs of AMD sufferers within the region.

On the other hand, Zeiss occupies a unique niche within the South Korea Dry Age-Related Macular Degeneration (AMD) Market by focusing on advanced diagnostic equipment and optical solutions essential for AMD diagnosis and monitoring. The company is recognized for its precision in ophthalmic technologies, which includes state-of-the-art imaging systems that enhance early detection and treatment planning for AMD. Zeiss capitalizes on its innovative technology and strong brand reputation, ensuring it maintains a formidable market presence in South Korea. Their key products include high-resolution imaging devices and diagnostic tools that provide comprehensive assessments of retinal health. Moreover, Zeiss's strategic collaborations and potential mergers and acquisitions bolster its capabilities in delivering advanced solutions tailored specifically for AMD care, thereby reinforcing its commitment to improving patient outcomes and staying ahead in a competitive market.

Key Companies in the South Korea Dry Age-Related Macular Degeneration (AMD) Market Include

• Bayer


• Zeiss


• Hector Pharmaceuticals


• Roche


• VIVUS


• Ophthotech


• Alcon


• Pfizer


• Kowa Company


• Novartis


• Santen Pharmaceutical


• HoffmannLa Roche


• Eyenovia


• Regeneron Pharmaceuticals

South Korea Dry Age-Related Macular Degeneration (AMD) Market Industry Developments

The South Korea Dry Age-Related Macular Degeneration (AMD) Market has seen notable developments in recent months. In July 2023, Bayer announced advancements in its therapeutic pipeline targeting dry AMD, aiming to enhance treatment efficacy and patient outcomes. Zeiss has been actively integrating innovative imaging technologies in its diagnostic tools, further augmenting early detection rates of AMD, which has raised awareness around the disease. Meanwhile, Regeneron Pharmaceuticals is experiencing growth in its market valuation, driven by the ongoing demand for its therapies, reflecting positively on the AMD sector in South Korea.

Recent collaborations have hinted at potential mergers in the market, particularly between companies like Ophthotech and significant investment firms interested in AMD treatment advancements. In September 2023, HoffmannLa Roche revealed ongoing clinical trials to evaluate new treatment protocols, indicating a commitment to address unmet medical needs. Growth in the South Korean aging population is also influencing trends, as the government has increased funding for ophthalmic research, thereby supporting ongoing innovations. The landscape continues to evolve as companies like Alcon and Novartis explore new partnerships and approaches to AMD, underscoring a dynamic market environment.

South Korea Dry Age-Related Macular Degeneration (AMD) Market Segmentation Insights

• Dry Age-Related Macular Degeneration (AMD) MarketStageOutlook


• early age-related macular degeneration


• intermediate age-related macular degeneration


• late age-related macular degeneration


• Dry Age-Related Macular Degeneration (AMD) MarketAge GroupOutlook


• above 75 years


• above 60 years


• above 40 years


• Dry Age-Related Macular Degeneration (AMD) MarketDiagnosis and TreatmentOutlook


• treatment


• diagnosis


• Dry Age-Related Macular Degeneration (AMD) MarketRoute of AdministrationOutlook


• oral


• injectables


• Dry Age-Related Macular Degeneration (AMD) MarketEnd UsersOutlook


• hospitalsclinics


• diagnostic centers


• academicresearch institutes

Report Attribute/Metric Source:	Details
MARKET SIZE 2023	110.0(USD Million)
MARKET SIZE 2024	120.0(USD Million)
MARKET SIZE 2035	320.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	9.326% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	Bayer, Zeiss, Hector Pharmaceuticals, Roche, VIVUS, Ophthotech, Alcon, Pfizer, Kowa Company, Novartis, Santen Pharmaceutical, HoffmannLa Roche, Eyenovia, Regeneron Pharmaceuticals
SEGMENTS COVERED	Stage, Age Group, Diagnosis and Treatment, Route of Administration, End Users
KEY MARKET OPPORTUNITIES	Aging population increasing prevalence, Advancements in treatment technologies, Growing awareness and education, Development of preventive therapies, Enhanced diagnostic tools and services
KEY MARKET DYNAMICS	Increasing aging population, Growing prevalence of AMD, Advancements in treatment options, Rising awareness of eye health, Government healthcare initiatives
COUNTRIES COVERED	South Korea